Vaccines Articles
Researchers at the University of Toledo have developed an experimental vaccine to prevent rheumatoid arthritis, one of the most common autoimmune disorders
The Centers for Medicare & Medicaid Services (CMS) is making it easier to check COVID-19 vaccination rates for nursing home staff and residents by making vaccination data available in a user-friendly format.
The U.S. Department of Health and Human Services’ Office for Civil Rights (OCR) issued guidance to help the public understand when the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule applies to disclosures and requests for information about whether a person has received a COVID-19 vaccine.
BioRender, an online tool for creating scientific figures, has created a robust, interactive COVID VacTracker that is maintained regularly and updated daily.
The CoVIg-19 Plasma Alliance now includes 11 plasma companies, and now also includes global organizations from outside the plasma industry.
Because research has shown the Bacillus Calmette-Guérin (BCG) tuberculosis vaccine boosts production of immune cells, it is currently being trialed in people as potential protection against COVID-19.
Two studies show the influenza (flu) and pneumonia vaccines lessen the risk of developing Alzheimer’s disease (AD) in the future.
A recent experiment found offering healthcare providers financial incentives and creating competition by informing clinics how their performance ranked relative to others were effective in increasing influenza (flu) vaccine rates among patients.
Two studies were conducted to determine whether measles infection causes long-term damage to immune memory.
Epidemiological data suggests populations with the highest measles-mumps-rubella (MMR) vaccination rates often have the fewest deaths from COVID-19.
Two analyses by the Centers for Disease Control and Prevention (CDC) show the influenza (flu) vaccine can reduce the likelihood of hospitalization in children and death in adults.
A Phase III study has found a trivalent hepatitis B virus (HBV) vaccine demonstrated superiority in adults 45 years and older and noninferior in adults older than 18 years compared with a monovalent vaccine.
